Resource use associated with Idiopathic Pulmonary Fibrosis

Application Number
15_157
Lay Summary

Idiopathic pulmonary fibrosis (IPF) is a debilitating respiratory disorder for which very few treatments have existed. While increasing attention has been paid to estimating the incidence and prevalence of the disease, little has been done to quantify the impact of this disease on NHS resources and what may explain the reasons for those impacts.

The purpose of this project will be to understand the NHS resource use and cost implications associated with IPF, taking a broad perspective that incorporates comorbidities related to IPF. The additional evidence to be provided by this study can shed further light on the need for increased resources directed at the management of IPF.

Technical Summary

Descriptive statistics and econometric analyses will be performed on the data to examine and explain the relationships between patient variables (such as demographics, disease severity, time since diagnosis, etc.) and NHS resource use.

The main analyses will consist of descriptive statistics and regression analysis to understand the incidence, prevalence, morbidity, and mortality associated with IPF. Resource use for both inpatient (number of stays, length of stay, etc.) and outpatient (general practitioner [GP] visits, emergency department visits, outpatient hospital visits, etc.) will subsequently be estimated both for those with and without IPF. This will consist of analysis of the GOLD dataset and the linked inpatient and outpatient HES files.

Subsequent analyses will scale these relationships up to the entire population served by the NHS and will incorporate cost estimates from published literature (the PSSRU) to estimate the annual monetary costs of IPF. If possible, a broader societal cost estimate will be undertaken via indirect cost estimates (missed workdays and labour force exit due to illness, informal caregiver needs, etc.) will also be incorporated, as would quality of life (via published EQ-5D catalogues). These will leverage the findings of the analyses of CPRD data, combining them with previously published data sources.

Collaborators

Irwin Tran - Chief Investigator - Roche
Jamie Garside - Collaborator - Roche
Mike Storm - Collaborator - Information Handling Services (IHS) Inc.
Robert Heathcote - Collaborator - Roche
Shadi Afzalnia - Collaborator - Roche

Linkages

HES Admitted Patient Care;HES Outpatient